Valuation: Evotec SE

Market Cap 590M 688M 551M 506M 951M 65.76B 966M 6.5B 2.55B 32.98B 2.58B 2.53B 109B P/E 2026 *
-2.83x
P/E 2027 * -7.72x
Enterprise Value 733M 854M 684M 628M 1.18B 81.67B 1.2B 8.08B 3.16B 40.96B 3.21B 3.14B 135B EV / Sales 2026 *
1.22x
EV / Sales 2027 * 1.05x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
Current month+6.70%
1 month+14.16%
3 months-20.98%
6 months-36.95%
Current year-30.97%
1 week 3.72
Extreme 3.724
3.72
1 month 3.49
Extreme 3.49
3.73
3 years 3.26
Extreme 3.262
21.51
5 years 3.26
Extreme 3.262
45.4
10 years 3.26
Extreme 3.262
45.4
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO - 01/05/2026
Chief Operating Officer - 01/05/2026
Director TitleAgeSince
Director/Board Member 58 19/06/2019
Director/Board Member 64 01/06/2021
Director/Board Member 59 10/06/2024
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-41.01%-81.71% 683M
+2.37%+2.30%+3.39%+23.26% 48.63B
-0.90%+4.42%+486.55%+617.53% 46.3B
+2.16%+5.42%+21.12%+93.00% 41.97B
+3.65%+3.13%+29.59%+16.28% 39.51B
-0.72%-7.79%+17.87%+47.98% 31.75B
+2.81%+1.62%+31.27%+146.62% 16.48B
+4.63%+2.30% - - 16.34B
+1.44%+1.09%+4.93%+31.00% 14B
+3.69%+2.34%+83.63%+44.85% 13.33B
Average +2.13%-0.47%+70.82%+104.31% 29.81B
Weighted average by Cap. +1.79%+0.01%+106.81%+155.09%

Financials

2026 *2027 *
Net sales 600M 699M 560M 514M 966M 66.82B 982M 6.61B 2.59B 33.51B 2.62B 2.57B 111B 719M 838M 672M 616M 1.16B 80.14B 1.18B 7.92B 3.1B 40.19B 3.15B 3.08B 133B
Net income -236M -275M -220M -202M -380M -26.28B -386M -2.6B -1.02B -13.18B -1.03B -1.01B -43.58B -60.37M -70.38M -56.37M -51.72M -97.26M -6.73B -98.86M -665M -260M -3.37B -264M -259M -11.15B
Net Debt 143M 167M 133M 122M 230M 15.92B 234M 1.57B 616M 7.98B 625M 612M 26.39B 162M 189M 151M 139M 261M 18.07B 266M 1.79B 700M 9.06B 710M 694M 29.96B
Logo Evotec SE
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
-
Date Price Change
20/08/26 EUR 3.724 0.00%
18/08/26 EUR 3.724 0.00%
17/08/26 EUR 3.724 0.00%
14/08/26 EUR 3.724 0.00%
13/08/26 EUR 3.724 0.00%
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
3.320EUR
Average target price
4.586EUR
Spread / Average Target
+38.12%

Quarterly revenue - Rate of surprise